alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 41



Consent of Amec Foster Wheeler Americas
Limited



We consent to the inclusion in this annual report on Form 40-F
of New Gold Inc., which is being filed with the United States Securities and Exchange Commission, of reference to Amec Foster Wheeler
Americas Limited, formerly known as AMEC Americas Limited, in connection with, and to the use of information derived from, the
technical report entitled "Technical Report on Feasibility Study for the Blackwater Project”, dated January 22, 2014,
included in the Annual Information Form of New Gold Inc. for the financial year ended December 31, 2014, and we consent to the
incorporation by reference of such information in the registration statement on Form S-8 (File No. 333-160500) of New Gold Inc.



Dated this 27th day of March, 2015



On behalf of Amec Foster Wheeler Americas Limited



|/s/ Kris Homer |                                             
|-------------- | --------------------------------------------
|Name:          | Kris Homer                                  
|Title:         | Vice President Operations,
    South America
```

[Federal Register Volume 76, Number 97 (Thursday, May 19, 2011)]
[Notices]
[Page 29021]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-12367]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Delegation of Authority No. 336]

Delegation of Authority by the Deputy Director of U.S. Foreign 
Assistance to the Managing Director of the Office of U.S. Foreign 
Assistance

    By virtue of the authority vested in the Secretary of State, 
including Section 1 of the State Department Basic Authorities Act, as 
amended (22 U.S.C. 2651a), and delegated to me by the Deputy Secretary 
of State in Delegation of Authority 307-1, I hereby delegate to the 
Managing Director of the Office of U.S. Foreign Assistance, to the 
extent authorized by law, all authorities and functions vested in the 
Deputy Director of Foreign Assistance by Delegation of Authority 307-1.
    Notwithstanding this delegation of authority, any function or 
authority delegated by this Delegation may be exercised by the 
Secretary, the Deputy Secretary, the Deputy Secretary for Management 
and Resources, or the Deputy Director of U.S. Foreign Assistance. Any 
reference in this delegation of authority to any statute or delegation 
of authority shall be deemed to be a reference to such statute or 
delegation of authority as amended from time to time.
    This delegation of authority shall be published in the Federal 
Register.

    Dated: April 15, 2011.
Robert H. Goldberg,
Deputy Director of U.S. Foreign Assistance.
[FR Doc. 2011-12367 Filed 5-18-11; 8:45 am]
BILLING CODE 4710-10-P
```
IN THE UNITED STATES DISTRICT COURT

FOR THE SOUTHERN DISTRICT OF OHIO

WESTERN DIVISION

MONTGOMERY COUNTY BOARD OF ) Case No. 3:18-cv-00293

COUNTY COMMISSIONERS, et al. )

)

Plaintiffs, ) Judge Thomas M. Rose

)

v. )

)

PURDUE PHARMA L.P., et al. ) ORDER

)

Defendants. )

Upon consideration it is herby

ORDERED that the Unopposed Motion of the Manufacturer Defendants to Stay the 

Date by Which to Respond to Plaintiffs
 Complaint and For an Extension of Time Pending 

Final Determination of Removal is GRANTED; it is further

ORDERED that the date by which the following Defendants shall answer, move, or 

otherwise respond to Plaintiffs’ Complaint is hereby stayed pending a final determination of 

removal: Purdue Pharma L.P., Purdue Pharma Inc., The Purdue Frederick Company Inc., Teva 

Pharmaceuticals USA, Inc., Cephalon, Inc., Johnson & Johnson, Janssen Pharmaceuticals, Inc., 

Ortho-McNeil-Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica, Inc., Endo Health Solutions 

Inc., Endo Pharmaceuticals Inc., Mallinckrodt, LLC, Mallinckrodt plc, and SpecGx LLC. and it is 

further

ORDERED that the following Defendants shall have thirty (30) days after the final 

determination of removal by which to answer, move, or otherwise respond to Plaintiff’s 

Complaint: Purdue Pharma L.P., Purdue Pharma Inc., The Purdue Frederick Company Inc., Teva 

Pharmaceuticals USA, Inc., Cephalon, Inc., Johnson & Johnson, Janssen Pharmaceuticals, Inc., 
Ortho-McNeil-Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica, Inc., Endo Health Solutions 

Inc., Endo Pharmaceuticals Inc., Mallinckrodt, LLC, Mallinckrodt plc, and SpecGx LLC.

IT IS SO ORDERED.

ENTERED this _31st day August, 2018

Thomas M. Rose

UNITED STATES DISTRICT JUDGE

or

Sharon L. Ovington

UNITED STATES MAGISTRATE JUDGE

s/ Thomas M. Rose
# United States Court of Appeals

For the Seventh Circuit

Chicago, Illinois 60604

Submitted December 11, 2008

Decided December 11, 2008

Before

JOHN L. COFFEY, Circuit Judge

JOEL M. FLAUM, Circuit Judge

MICHAEL S. KANNE, Circuit Judge

No. 08

‐ 2446

UNITED STATES OF AMERICA,

Plaintiff

‐ Appellee

,

v.

TROY MILLER,

Defendant

‐ Appellant

. Appeal from the United States District

Court for the Southern District of Indiana,

Evansville Division.

No. 3:06CR00038

‐ 014

Richard L. Young,

Judge

.

O R D E R

In 2008 Troy Miller entered into an agreement to plead guilty to one count of

conspiracy to possess with the intent to distribute cocaine. See 21 U.S.C. §§ 846, 841(a)(1).

The parties agreed on page three of Miller’s plea agreement to a specific sentence of 120

months’ imprisonment—the mandatory minimum given the amount of cocaine and Miller’s

prior conviction for a felony drug offense. See 21 U.S.C. § 841(b)(1)(B); F ED

. R. C RIM

. P.

11(c)(1)(C). The district court accepted the plea agreement and sentenced Miller, as agreed,

to 120 months’ imprisonment. See F ED

. R. C RIM

. P. 11(c)(3)(A). NONPRECEDENTIAL DISPOSITION

To be cited only in accordance with

Fed. R. App. P. 32.1No. 08

‐ 2446 Page 2

Miller filed a notice of appeal, but the government has moved to dismiss on the

ground that Miller waived his right to appeal in the plea agreement. See United States v.

Mason

, 343 F.3d 893 (7th Cir. 2003). Miller’s lawyer concedes the point and agrees that the

appeal should be dismissed. Miller himself opposes the government’s motion. See C IR

. R.

51(b).

The appeal waiver aside, a defendant who agrees to a specific sentence cannot

appeal the sentence imposed except in three narrow circumstances: if his guilty plea was

involuntary, if the sentence he received is greater than the sentence he bargained for, or if

his sentence was imposed in violation of law. See 18 U.S.C. § 3742(a)(1), (c)(1); United States

v. Gibson

, 490 F.3d 604, 607 (7th Cir. 2007); United States v. Cieslowski

, 410 F.3d 353, 363

‐ 64

(7th Cir. 2005); United States v. Barnes

, 83 F.3d 934, 941 (7th Cir. 1996). Miller does not want

his plea set aside, eliminating the first possibility. The second possibility is not tenable

because Miller’s prison sentence tracks the agreement. As for the third possibility, Miller’s

sentence is the lowest permitted by law. See 21 U.S.C. § 841(b)(1)(B).

Even if Miller’s appeal was not precluded by § 3742(a)(1) and (c)(1), his plea

agreement includes a clear and unambiguous appellate waiver, which is enforceable

because the record shows that he knowingly and voluntarily entered into the agreement.

See United States v. Linder

, 530 F.3d 556, 561 (7th Cir. 2008); United States v. Blinn

, 490

F.3d 586, 588 (7th Cir. 2007).

Accordingly, we GRANT government’s motion to DISMISS the appeal.
# Navy Establishes COVID-19 Surveillance Testing Program

### 25 Jun 2020

The U.S. Navy established a surveillance testing program, called Sentinel Surveillance Testing (SST), to test asymptomatic service members for COVID-19 June 25. This testing will enable the service to detect asymptomatic COVID-positive individuals, assist in bounding an outbreak, and detect any potential second wave or resurgence of the disease early.The Navy will conduct testing and collect reports in two-week increments. The first phase of SST begins today.Vice Adm. Phillip Sawyer, Deputy Chief of Naval Operations for Operations, Plans, and Strategy, was one of the first to be swabbed in the Pentagon as part of the first phase, “I was happy to volunteer to get tested as part of this program. This virus doesn’t discriminate based on rank, so it’s important to make sure we are staying vigilant across the force.”The goal is to minimize the transmission of COVID-19 across the force and ultimately create a COVID free bubble around units prior to, and while, deployed.  Previously, the service’s preventative efforts were primarily focused and maintaining COVID-free deployable units. There is now sufficient testing capacity to expand those efforts more broadly across the Navy.This expanded effort to protect the force involves testing asymptomatic populations to detect the disease early and to focus public health actions in response.  SST is designed to break the chain of disease transmission. “Our nation is entering a dangerous period of complacency and COVID fatigue that we can’t succumb to. The military must not let its guard down—the Navy in particular,” said Rear Adm. Karl Thomas, Assistant Deputy Chief of Naval Operations for Operations, Plans, and Strategy. “SST will help detect asymptomatic individuals and thus protect our forces, and allow leadership to understand transmission patterns to adjust processes and measures when and where needed.”This roll out plan will be accomplished in phases as testing capacity becomes available and processes are refined.  Populations with higher risk for infection and transmission will be the initial focus.These increased risk populations include health care workers, training teams who frequently visit a variety of commands, security guards at entry control points, childcare workers, and galley employees among others. Additionally the Navy will test instructors and students at learning centers and school houses, fleet readiness centers, and high density office personnel.Continued testing has the added benefit of reinforcing public health mitigation measures and will continue to inform the Navy’s understanding of COVID-19 transmission.For more information about NAVADMIN 178/20, go to https://www.public.navy.mil/bupers-npc/reference/messages/Documents/NAVADMINS/NAV2020/NAV20178.txt

More Details
#### John W. ICKES, Plaintiff-Appellant, v. Jason WILSON, Facility Director; Twalla Moore, Property Dept. Supervisor, Defendants-Appellees.

No. 16-6756

United States Court of Appeals, Fourth Circuit.

Submitted: November 17, 2016

Decided: November 22, 2016

John Woodward Ickes, Jr., Appellant Pro Se. Pamela Brown Beckner, Office of the Attorney General of Virginia, Richmond, Virginia, for Appellees.

Before GREGORY, Chief Judge, and MOTZ and TRAXLER, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Unpublished opinions are not binding precedent in this circuit.

PER CURIAM:

John Woodward Ickes, Jr., appeals the district court’s order granting Defendants’ motion for summary judgment in this civil rights action. We have reviewed the record and find no reversible error. Accordingly, we affirm for the reasons stated by the district court. Ickes v. Wilson, No. 1:15-cv-00605-LO-IDD, 2016 WL 2853534 (E.D. Va. filed May 11, 2016 & entered May 13, 2016). We dispense with oral argument because the facts arid legal contentions are adequately presented in the materials before this court and argument would not aid the decisional process.

AFFIRMED
#### UNITED STATES of America, Plaintiff-Appellee, v. Luis Enrique SANCHEZ-CASTRO, Defendant-Appellant.

No. 17-6223

United States Court of Appeals, Fourth Circuit.

Submitted: June 20, 2017

Decided: June 23, 2017

Luis Enrique Sanchez-Castro, Appellant Pro Se. Robert Michael Hamilton, Harry L. Hobgood, Angela Hewlett Miller, Assistant United States Attorneys, Randall Stuart Galyon, OFFICE OF THE UNIT*132ED STATES ATTORNEY, Greensboro, North Carolina, for Appellee.

Before SHEDD, WYNN, and DIAZ, Circuit Judges.

PER CURIAM:

Luis Sanchez-Castro appeals from the district court’s order denying his 18 U.S.C. § 3582(c)(2) (2012) motion for reduction of his sentence based on Amendment 782 to the U.S. Sentencing Guidelines Manual. We have reviewed the record and find no reversible error. Accordingly, we affirm for the reasons stated by the district court. *United States v. Sanchez-Castro,*No. 1:13-cr-00086-TDS-1 (M.D.N.C. Jan. 23, 2017). We deny Sanchez-Castro’s motion for transcripts at government expense, and we dispense with oral argument because the facts and legal contentions are adequately presented in the materials before this court and argument would not aid the decisional process.

*AFFIRMED*
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  In connection with the filing of the Annual Report on Form 40F for the fiscal year ended December 31, 2013 (the “Report”) by New Gold Inc. (the “Company”), I, Brian W. Penny, as Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:


1.
The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and


2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.







Dated: March 28, 2014




“Brian Penny”




Brian W. Penny


Chief Financial Officer
Exhibit 32.1

      Certification of Chief Executive Officer and Chief Financial Officer
                       pursuant to 18 U.S.C. Section 1350,
                             as adopted pursuant to
                  Section 906 of the Sarbanes-Oxley Act of 2002
         ---------------------------------------------------------------

In connection with the Quarterly Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 on Form 10-Q of Immtech International, Inc. (the
"Company") for the quarterly period ended June 30, 2003, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, T.
Stephen Thompson, President and Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

      1)   the Report fully complies with the requirements of Section 13(a) or
           15(d) of the Securities Exchange Act of 1934, as amended; and

      2)   the information contained in the Report fairly presents, in all
           material respects, the financial condition and results of operations
           of the Company.

                       /s/ T. Stephen Thompson
                       -------------------------------------------
                       Name:  T. Stephen Thompson
                       Title: President & Chief Executive Officer
                       Date:  August 14, 2003
I 

117TH CONGRESS 

1ST SESSION H. R. 1166 

To allow individuals to choose to opt out of the Medicare part A benefit. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 18, 2021 

Mr. PALMER (for himself, Mr. BROOKS, Mr. ROY, Mr. CLOUD, and Mr. NORMAN) introduced the following bill; which was referred to the Committee 

on Ways and Means 

A BILL 

To allow individuals to choose to opt out of the Medicare 

part A benefit. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Retirement Freedom 

5 Act’’. 

6 SEC. 2. ALLOWING INDIVIDUALS TO CHOOSE TO OPT OUT 

7 OF THE MEDICARE PART A BENEFIT. 

8 Any individual who is otherwise entitled to benefits 

9 under part A of title XVIII of the Social Security Act may 

10 elect (in such form and manner as may be specified by 


khammond on DSKJM1Z7X2PROD with BILLS
2 

•HR 1166 IH

1 the Secretary of Health and Human Services) to opt out 

2 of such entitlement. Notwithstanding any other provision 

3 of law, in the case of an individual who makes such an 

4 election, such individual— 

5 (1) may (in such form and manner as may be 

6 specified by the Secretary) subsequently choose to 

7 end such election and opt back into such entitlement 

8 (in accordance with a process determined by the 

9 Secretary) without being subject to any penalty; 

10 (2) shall not be required to opt out of benefits 

11 under title II of such Act as a condition for making 

12 such election; and 

13 (3) shall not be required to repay any amount 

14 paid under such part A for items and services fur15 nished prior to making such election. 

Æ 


khammond on DSKJM1Z7X2PROD with BILLS
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF THE BISYS GROUP, INC. AND SUBSIDIARIES FOR
THE THREE MONTHS ENDED SEPTEMBER 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-2001
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          48,222
<SECURITIES>                                         0
<RECEIVABLES>                                  124,606
<ALLOWANCES>                                     3,278
<INVENTORY>                                          0
<CURRENT-ASSETS>                               200,749
<PP&E>                                         123,312
<DEPRECIATION>                                  58,001
<TOTAL-ASSETS>                                 649,858
<CURRENT-LIABILITIES>                          241,319
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,131
<OTHER-SE>                                     396,758
<TOTAL-LIABILITY-AND-EQUITY>                   649,858
<SALES>                                              0
<TOTAL-REVENUES>                               161,441
<CGS>                                                0
<TOTAL-COSTS>                                   95,958
<OTHER-EXPENSES>                                10,951
<LOSS-PROVISION>                                   823
<INTEREST-EXPENSE>                               2,747
<INCOME-PRETAX>                                 21,344
<INCOME-TAX>                                     8,432
<INCOME-CONTINUING>                             12,912
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    12,912
<EPS-BASIC>                                       0.23
<EPS-DILUTED>                                     0.22


</TABLE>
1 

# The Dow Chemical 

# Company

Misting In Solventless Adhesives

12

23

34

45

56

67

78

89

910

1011

1112

1213 

# Summary

+ Misting is a function of :

+ Adhesive rheology

+ Configuration of the coating station

+ Adhesive and roll temperature

+ Line speed



## + Misting can be handled by :

+ Changing adhesive system

+ Increasing adhesive pool and application roll temperature



### + Lowering line speed

+ Containment

13
EX PARTE James ROBINSON

CR-16-0201

Court of Criminal Appeals of Alabama.

February 1, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Mand. pet. denied.
Section 409A Amendments to Option Award Agreements



 Exhibit 10.11.5 
 TRAILER BRIDGE, INC. 
 SECTION 409A AMENDMENTS 
 TO 
 OPTION AWARD AGREEMENTS

 Pursuant to Section 7.1 of the Trailer Bridge, Inc. Stock Incentive Plan (“Key Employee Plan”) and Section 7.1 of
the Trailer Bridge, Inc. Non-Employee Director Stock Incentive Plan (“Non-Employee Director Plan”), the Compensation Committee, in its capacity as administrator of the two plans, hereby amends each outstanding Option Award Agreement
between Trailer Bridge, Inc. (“Company”) and a Key Employee or Non-Employee Director entered into under the Key Employee Plan or Non-Employee Director Plan as follows in order to bring each such Option Award Agreement into full compliance
with all applicable requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and to make certain other changes which are beneficial to such Key Employees and Non-Employee Directors. 
 The following amendments shall be effective as of January 1, 2009. 
 1. Initially capitalized terms used in this Amendment and not expressly otherwise defined herein shall have the meanings given to such terms under the Key Employee Plan, Non-Employee Director Plan or applicable Option
Award Agreement. 
 2. It is the intent of the Committee that under no circumstances may an Option be exercised after its Expiration Date. In
order to clarify this intent, the last sentence of Section 1(a) of the Option Award Agreements issued under the Key Employee Plan are hereby amended in its entirety to provide as follows: 
 “The Option may not be exercised prior to the Initial Exercise Date set forth in the signature page hereof or after the Expiration Date set forth
thereon. Furthermore, except as otherwise expressly provided herein, the Option shall not be exercisable after the termination of the Optionee’s employment with the Company or any Affiliate of the Company (“Employment”).”

 3. Section 1(b) of each Option Agreement is hereby amended by the addition of the following sentence at the end thereof: 

“The aggregate purchase price for the Shares for which the Option is exercised may also be paid by having the Company reduce the number of Shares
delivered to Optionee upon exercise. 
 4. Section 9 is hereby amended by the addition of the following new sentence at the end thereof:

 “In no event shall the Committee adjust the terms of the Option in a manner that could cause the Option to be treated as a grant of an
new Option for purposes of Section 409A of the Code and Treas. Reg. § 1.409A-1(b)(5)(v).” 







 5. Except as otherwise expressly provide above, this Amendment shall not affect the terms and conditions
of an Option and each Option Award Agreement shall continue in full force and effect following this Amendment. This Amendment shall not change the number of shares subject to an Option, the exercise price of an Option, the vesting schedule of an
Option or otherwise modify an Option in any way that could cause the Option, as so amended, to be deemed a grant of a new option pursuant to Treas. Reg. §1.409A-1(b)(5)(v). 
 Approved by the Compensation Committee on December     , 2008 
  

 2
A.K., Mother of M.K., J.K., M.K., A.K., and C.C., Children, Appellant, v. DEPARTMENT OF CHILDREN AND FAMILIES, Appellee.

Case No. 5D17-2438

District Court of Appeal of Florida, Fifth District.

Decision filed January 31, 2018

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.